3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
3
Thoracic
2
Genitourinary
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Radiosurgery
22
Nivolumab
21
Ipilimumab
19
pembrolizumab
15
Temozolomide
11
dabrafenib
10
binimetinib
10
encorafenib
8
Cyclophosphamide
8
trametinib
7
Magnetic Resonance Spectroscopy
7
Bevacizumab
6
fludarabine
5
cobimetinib
5
Specimen Handling
5
CTLA-4 Antigen
5
fludarabine phosphate
3
aldesleukin
3
Vemurafenib
3
Thalidomide
3
Paclitaxel
3
Oxaliplatin
3
Interleukin-2
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
ulixertinib
2
tovorafenib
2
relatlimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Interleukin-15
×
CNS
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled